

# BetterLife Pharma Inc

10:05 15 Oct 2020

## BetterLife Pharma chooses contract research organization for Australia coronavirus trial of AP-003

BetterLife Pharma Inc (CSE:BETR) (OTCQB:BETRF) has engaged the clinical research organization (CRO) Pharmaceutical Solutions Ltd to manage its clinical trial of AP-003 as a treatment for mild-to-moderate coronavirus (COVID-19) cases at research sites across Australia.

The clinical trial, expected to launch later this year, will test AP-003, BetterLife's inhaled recombinant human alpha 2b interferon drug, against a placebo. The trial, which the company claims is the first of its kind in Australia, is expected to recruit 150 patients.

Interferons are a natural part of the body's innate immune system that are induced by viral infection, the company said, providing the body's first line of defense. Interferon production is inhibited by the virus responsible for COVID-19, the company explained, but AP-003 is designed to bypass the COVID-19-induced interferon production blockade.

### READ: BetterLife Pharma announces VirTrial as patient monitoring partner for COVID-19 study in Australia to test efficacy of AP-003

BetterLife believes that AP-003 could lessen the severity and duration of COVID-19 and decrease the need for hospital admissions.

"BetterLife's treatment offers real promise to people who have a mild to moderate case of COVID-19," Pharmaceutical Solutions managing director, Jacquie Palmer said in a statement. "It is exciting to bring this novel trial to Australia and to see the region help in the global fight against COVID-19."

The randomized, double-blind, placebo-controlled trial will take place across several research sites in Australia, the company said.

"The Pacific region is an attractive clinical research environment which benefits from a world-class healthcare system that is not overburdened by COVID-19," Palmer added. "The region has an engaged patient population and benefits from accelerated ethics and regulatory processes."

BetterLife and Pharmaceutical Solutions will conduct the trial virtually to reduce the exposure of the investigative sites to COVID and allow the participants to remain at home, the company said. To make it work, the trial will rely on video consultations, questionnaires and mobile app technology.

"We are pleased to have Pharmaceutical Solutions as part of our team to support us in our clinical strategy for IFN-?2b as a therapeutic for COVID-19," BetterLife CEO Ahmad Doroudian said. "We have assembled an exemplary team of scientific, clinical and regulatory experts, and now with Pharmaceutical Solutions as our Australian CRO we can quickly move forward with our trial."

**Price:** 0.42096

**Market Cap:** \$15.56 m

### 1 Year Share Price Graph



November 2019 May 2020 November 20

### Share Information

**Code:** BETRF

**Listing:** OTCQB

<b>52 week</b>	<b>High</b>	<b>Low</b>
	2.21	0.0993

**Sector:** Pharma & Biotech

**Website:** abetterlifepharma.com

### Company Synopsis:

*BLife Therapeutics, a wholly-owned subsidiary of BetterLife Pharma Inc. , is focused on the development of its patent pending Interferon formula, AP-003, for the treatment and prevention of severe COVID-19 disease. It's parent, Better Life Pharma Inc.*

action@proactiveinvestors.com

The lead clinician in the study, Professor Stephen Hall, from Emeritus Research in Victoria, pointed to the prior success interferons have had in treating the virus.

"We are thrilled to have Betterlife's AP-003 available to us to test in clinical trials in Australia to tackle mild to moderate presentations of COVID-19," Hall said. "An exploratory trial from hard-hit Wuhan has demonstrated a significant reduction of the viral load using a interferon alpha-2b. Interferon-based therapies are now also undergoing clinical trials in Britain, Germany and the US."

Contact Andrew Kessel at [andrew.kessel@proactiveinvestors.com](mailto:andrew.kessel@proactiveinvestors.com)

Follow him on Twitter [@andrew\\_kessel](https://twitter.com/andrew_kessel)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of BetterLife Pharma Inc named herein, including the promotion by the Company of BetterLife Pharma Inc in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).